Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset

Byoung Chul ChoHidetoshi HayashiJong-Seok LeeSe-Hoon LeePongwut DanchaivijitrYing ChengBaogang LiuAdlinda AlipHailin XiongSoon Hin HowGee-Chen ChangJames Chih-Hsin YangHiroshige YoshiokaMehmet Ali Nahit ŞendurKumar PrabhashKoichi AzumaYun-Gyoo LeeChien-Chung LinShingo MatsumotoPatrapim SunpaweravongYichuan XiaMelissa MartinezJoshua M. BaumlSeema SethiShun Lu2026-02-052026-02-052025-0610.1016/j.lungcan.2025.108496https://scholars.csmu.edu.tw/handle/123456789/5231[SDGs]SDG3Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subsetjournal-article